Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Sep
19
2023
VIRTUAL
9:30—10:30 AM ET / 2:30-3:30 PM BST
August 09, 2023
New research from the Indian School of Business (Max Institute of Healthcare Management) and CGD has assessed the cost-effectiveness of genomic surveillance in India. This event dives into the results of the new research and explores the wider implications of WGS on pandemic preparedness, prevention...
Jul
20
2023
VIRTUAL
10:00—11:00 AM ET / 3:00-4:00 PM BST
June 14, 2023
Join the Center for Global Development for a virtual panel discussion reflecting on lessons learned from COVAX for future global and regional response efforts to ensure rapid and equitable access to vaccines and other medical countermeasures.
Mar
7
2023
VIRTUAL
9:30—10:45 AM Eastern Time (US and Canada)
February 27, 2023
Following promising clinical trial results, the first oral antiviral treatments for COVID-19 received emergency use authorization in late 2021. Since then, manufacturers, global health funders, and other partners have focused on ramping up global supply, including via test-and-treat pilot programs. ...
Nov
4
2021
11:00—12:00 PM Eastern Time (US and Canada)
October 27, 2021
After earlier calls for transparency in the global deployment of COVID-19 vaccine, we’ve seen progress: in addition to UNICEF’s COVID-19 Vaccine Dashboard launched in December 2020, the Task Force on COVID-19 Vaccines, Therapeutics, and Diagnostics – launched in June 2021 – houses a central reposito...
Jul
13
2021
2:00—3:15 PM Washington DC Time
July 07, 2021
Ensuring access, affordability, and equity to essential medicines and other health products is critical to strong health systems. COVID-19 has shown how quickly failing to safeguard these principles reverses progress towards universal access to health and universal health coverage. Coordination and ...
Jun
16
2021
9:00—10:15 AM Washington DC time
June 03, 2021
How much about COVID-19 purchasing agreements is available in the public domain? And how can data sharing and contract publication help policymakers decide how much vaccine countries should buy, who should pay, and how they should be delivered and distributed?